Latest News and Press Releases

Allschwil, 05. Juni 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren...

Allschwil, Switzerland, June 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial...

TORONTO and HAIFA, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that on May 22, 2025,...

ROUYN-NORANDA, Quebec, June 02, 2025 (GLOBE NEWSWIRE) -- GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS...

L’ancien PDG de la Commerzbank Manfred Knof devient conseiller stratégique de DeFi Technologies et président de Valour. Il fait preuve d’une expérience de plusieurs dizaines d’années dans le domaine...

DeFi Technologies ernennt den ehemaligen CEO der Commerzbank, Dr. Manfred Knof, zum strategischen Berater von DeFi Technologies und zum Vorsitzenden von Valour. Er bringt jahrzehntelange...

DeFi Technologies appoints former Commerzbank CEO Dr. Manfred Knof as Strategic Advisor to DeFi Technologies and Chairman of Valour.

NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association

TORONTO, May 27, 2025 (GLOBE NEWSWIRE) -- Captor Capital Corp. (“Captor” or the “Company”) (CSE: CPTR) is excited to announce a significant milestone in its growth strategy with the acquisition of...

TORONTO and HAIFA, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-stage biotechnology company...